Aerie Pharmaceuticals Inc. intends to commercialize its glaucoma drug candidates itself, but positive Phase III results for both topical therapies, including new data for Roclatan, may make the company an acquisition target for biopharmaceutical firms that are looking to buy late-stage assets.
Irvine, Calif.-based Aerie reported after the stock market closed on May 24 that it will seek US FDA approval for...







